Unraveling the Potential of Specialized Allied Health Therapy in Parkinson’s Disease
Objective: To investigate discipline-specific effects of specialized Allied Health Therapy on the incidence of Parkinson’s Disease (PD)-related complications. Background: Specialized physiotherapy has been shown to…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on dyskinesia, psychosis-like behaviours, and parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effect of LY-404,039 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD). Background:…Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques
Objective: To determine whether striatal CaV1.3 gene silencing ameliorates levodopa-induced dyskinesias (LID) in the preclinical gold-standard non-human primate (NHP) model without altering levodopa’s antiparkinsonian benefit.…Pilot case on the use of transcranial pulsed current stimulation(tPCS) in a patient with cervical dystonia(CD)
Objective: To demonstrate the efficacy of tPCS on a patient with CD Background: CD is a common adult-onset dystonia. Abnormal sensorimotor integration and maladaptive plasticity…Correlation between 3 Tesla Brain MRI Nigrosome-1 imaging and SPECT 123I-Ioflupane in parkinsonian disorders
Objective: To correlate nigrosome-1 (NG1) imaging and SPECT 123I-Ioflopane findings to determine the feasibility and diagnostic value of NG1 imaging in a real-world clinical setting.…Motor-Related and Cognition-Related Safety of Pimavanserin in Patients with Parkinson’s Disease Psychosis (PDP)
Objective: Evaluate motor- and cognition-related safety in pimavanserin-treated patients with PDP. Background: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only US FDA-approved treatment for…DIFFERENCE IN MOTOR AND NONMOTOR SYMPTOMS BETWEEN YOUNG AND LATE ONSET PARKINSON`S DISEASE
Objective: To evaluate difference in prevalence of nonmotor symptoms and severity of autonomic and motor symptoms between patients with young (YOPD) and late onset (LOPD)…Characterization of neuromelanin MRI as a potential Parkinson’s Disease biomarker in a multi-site longitudinal study
Objective: To investigate (1)longitudinal change and (2)cross-sectional vendor differences in neuromelanin MRI in substantia nigra pars compacta(SNpc) in PD patients. Background: Neuromelanin(NM) MRI is a…Outcome and mortality of hospital admission with COVID-19 in parkinsonian syndromes
Objective: To evaluate features associated with poor outcome and mortality of COVID-19 in people with Parkinson’s disease (PD) and atypical Parkinsonian syndromes (APS) in a…Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD)
Objective: To establish a large, longitudinal online cohort linked with a selected, intensively assessed cohort of people with and without PD to characterize development and…
- « Previous Page
- 1
- …
- 90
- 91
- 92
- 93
- 94
- …
- 153
- Next Page »